MIG Capital

Biocrates Life Sciences AG is a biotechnology company based in Innsbruck, Austria, specializing in targeted metabolic phenotyping solutions. Founded in 2002, the company develops and markets mass-spectrometry based kits and services that facilitate the analysis of endogenous metabolites. These tools are essential for discovering and validating biomarkers associated with complex multifactorial diseases, including cancer and neurodegenerative disorders. Biocrates provides a comprehensive metabolomics platform that integrates automated sample preparation workflows with advanced mass-spectrometric techniques, enabling rapid and reliable identification of hundreds of metabolites. Their products and services cater to a wide range of research areas, such as cardiovascular health, diabetes, endocrinology, pharmacology, and more. Biocrates Life Sciences distributes its solutions through authorized partners across various regions, including the Middle East, Europe, and parts of Asia.

AFFiRiS AG is a biotechnology company based in Vienna, Austria, specializing in the development and manufacture of peptide-based vaccines aimed at the therapeutic treatment of chronic diseases with significant unmet medical needs. Founded in 2003, the company focuses on creating tailored vaccines for a range of conditions, including Alzheimer’s disease, Parkinson’s disease, atherosclerosis, hypertension, diabetes, psoriasis, allergies, asthma, and Huntington’s disease, among others. Through its innovative approach, AFFiRiS seeks to address critical health challenges and improve patient outcomes in various therapeutic areas.

AFFiRiS AG is a biotechnology company based in Vienna, Austria, specializing in the development and manufacture of peptide-based vaccines aimed at the therapeutic treatment of chronic diseases with significant unmet medical needs. Founded in 2003, the company focuses on creating tailored vaccines for a range of conditions, including Alzheimer’s disease, Parkinson’s disease, atherosclerosis, hypertension, diabetes, psoriasis, allergies, asthma, and Huntington’s disease, among others. Through its innovative approach, AFFiRiS seeks to address critical health challenges and improve patient outcomes in various therapeutic areas.

AFFiRiS AG is a biotechnology company based in Vienna, Austria, specializing in the development and manufacture of peptide-based vaccines aimed at the therapeutic treatment of chronic diseases with significant unmet medical needs. Founded in 2003, the company focuses on creating tailored vaccines for a range of conditions, including Alzheimer’s disease, Parkinson’s disease, atherosclerosis, hypertension, diabetes, psoriasis, allergies, asthma, and Huntington’s disease, among others. Through its innovative approach, AFFiRiS seeks to address critical health challenges and improve patient outcomes in various therapeutic areas.

Biocrates Life Sciences AG is a biotechnology company based in Innsbruck, Austria, specializing in targeted metabolic phenotyping solutions. Founded in 2002, the company develops and markets mass-spectrometry based kits and services that facilitate the analysis of endogenous metabolites. These tools are essential for discovering and validating biomarkers associated with complex multifactorial diseases, including cancer and neurodegenerative disorders. Biocrates provides a comprehensive metabolomics platform that integrates automated sample preparation workflows with advanced mass-spectrometric techniques, enabling rapid and reliable identification of hundreds of metabolites. Their products and services cater to a wide range of research areas, such as cardiovascular health, diabetes, endocrinology, pharmacology, and more. Biocrates Life Sciences distributes its solutions through authorized partners across various regions, including the Middle East, Europe, and parts of Asia.

PDC Biotech GmbH is a biotechnology company based in Vienna, Austria, specializing in the development of innovative therapeutics for the treatment of preterm labor and primary dysmenorrhea, addressing significant unmet medical needs. Founded in 2008, the company focuses on a pipeline of products that target the prostaglandin F2α (FP) receptor, including synthetic octapeptides designed as allosteric modulators of this receptor. Key products in development include PDC31 and the PDC41 Series, a non-intravenous formulation intended for self-administration by patients. PDC Biotech employs various delivery methods for its formulations, such as nasal, sublingual, pulmonary, vaginal, and rectal suppositories. The company has secured exclusive worldwide rights to a family of FP receptor antagonists, enabling it to advance its therapeutic offerings in the biopharmaceutical sector.

Biocrates Life Sciences AG is a biotechnology company based in Innsbruck, Austria, specializing in targeted metabolic phenotyping solutions. Founded in 2002, the company develops and markets mass-spectrometry based kits and services that facilitate the analysis of endogenous metabolites. These tools are essential for discovering and validating biomarkers associated with complex multifactorial diseases, including cancer and neurodegenerative disorders. Biocrates provides a comprehensive metabolomics platform that integrates automated sample preparation workflows with advanced mass-spectrometric techniques, enabling rapid and reliable identification of hundreds of metabolites. Their products and services cater to a wide range of research areas, such as cardiovascular health, diabetes, endocrinology, pharmacology, and more. Biocrates Life Sciences distributes its solutions through authorized partners across various regions, including the Middle East, Europe, and parts of Asia.